Every year in the U.S., 22,000 to 24,000 women are diagnosed with ovarian cancer. Patient survival depends upon the responses to chemotherapy. Recently, study results involving mirvetuximab soravtansine, an antibody drug conjugate that targets folate receptor alpha expression (the expression of folate receptor alpha is encountered in most ovarian cancers and is indicative of tumor aggressiveness), has demonstrated significant clinical efficacy in heavily-pretreated ovarian cancer patients.
Every year in the U.S., 22,000 to 24,000 women are diagnosed with ovarian cancer.
In the Soraya study, a total of 106 platinum-resistant ovarian cancer patients who were treated with a median of three prior therapies, exhibited a response rate of 32.4% (the tumors deceased in size) for a median duration of 5.9 months following treatment with mirvetuximab soravtansine. Mirvetuximab soravtansine was also fairly well-tolerated, although 41% of patients experienced blurred vision related to the treatment and keratopathy, a disease of the cornea, occurred in 35% of patients; the ocular deficits were all reversible. Mirvetuximab soravtansine may confer significant survival benefits in ovarian cancer, especially in patients who exhibit high levels of folate receptor alpha expression
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media: